<DOC>
	<DOCNO>NCT02734407</DOCNO>
	<brief_summary>The Endurance Trial Phase IV open label clinical study ass need ongoing intravitreal aflibercept injection 3-year VISTA DME ( VGFT-OD-1009 ) endpoint . Subjects treat intravitreal aflibercept injection pro nata ( PRN ) base presence CR-DME ( Clinically Relevant-DME ) . In addition , subject meet re-treatment criterion eligible focal laser treatment every 90 day</brief_summary>
	<brief_title>Long-Term Efficacy Safety Aflibercept Intravitreal Injections Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>The Endurance3 Trial Phase IV open label study assess need ongoing intravitreal aflibercept injection 3 year VISTA DME ( VGFT-OD-1009 ) endpoint . Subjects treat intravitreal aflibercept injection pro nata ( PRN ) upon presence CR-DME ( Clinically Relevant DME ) note OCT ( Optical Coherence Tomography ) image examination . In addition , subject meet re-treatment criterion eligible focal laser treatment every 90 day .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Enrolled complete VISTA DME ( VGFTOD1009 ) clinical trial Willing able comply clinic visit studyrelated procedure Provide sign informed consent Enrollment trial within 12 week trial activation Prior treatment antiVEGF therapy study eye within 28 day baseline Pregnant breastfeed woman Sexually active ment woman childbearing potential unwilling practice adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>